SPARC
Drug Manufacturers - Specialty & Generic · SPARC
Small CapHealthcareHigh Growth
Anilkumar Raghavan
Chief Executive Officer · Pragmatic
Company DNA
Innovation-Led
About
SPARC is a Small Cap company in the Healthcare sector, listed on NSE as SPARC. With a market cap of ₹4K Cr and revenue of ₹72 Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Disruptor approach to innovation, the company operates at a Steady-Marathon pace. Specialized drug research company focused on R&D where scientific outcome is the primary KPI. Its strategic mandate: Success depends on long-term R&D breakthroughs and bringing a strong pipeline of specialty pharmaceutical products to market.
FAQ
What kind of company is SPARC?
SPARC is a Small Cap Healthcare company (SPARC) in the High Growth phase with a market cap of ₹4K Cr. It is classified as Innovation-Led in culture.
What is SPARC's culture and work environment like?
SPARC has a Innovation-Led culture with Disruptor innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Specialized drug research company focused on R&D where scientific outcome is the primary KPI.
Who leads SPARC?
SPARC is led by Anilkumar Raghavan (Chief Executive Officer), a Pragmatic leader with 30 years of experience.
What are SPARC's financials?
SPARC reported revenue of ₹72 Cr in FY25 with a 5-year revenue CAGR of -19.4%. Operating margin: -465.5%. Market cap: ₹4K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationDisruptor
PaceSteady-Marathon
PurposeMission-First
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
Specialized drug research company focused on R&D where scientific outcome is the primary KPI.
Mandate
Success depends on long-term R&D breakthroughs and bringing a strong pipeline of specialty pharmaceutical products to market.
Success depends on long-term R&D breakthroughs and bringing a strong pipeline of specialty pharmaceutical products to market.
Financials
Revenue FY25₹72 Cr
PAT FY25₹-3425094000
Rev CAGR 5Y-19.4%
OPM-465.5%
NPM-477.3%
ROE157.9%
ROCE863.1%
P/E—
Fwd P/E2.1
P/B-11
D/E—
Mkt Cap₹4K Cr
Promoter73%
Institutional2.6%
Similar Culture
Could You Lead SPARC?
Take the Genome Benchmark →